Art. -Nr.: HY-115714

CDK9-IN-12

Name: CDK9-IN-12
Brand: MedChemExpress
SKU: HY-115714
Price: 170.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC₅₀ value of 5.41 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.65%
CAS. Nr.: 1942843-54-0
Formel: C₂₁H₁₉ClN₄O
Molecular Weight:378.85

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

CDK9-IN-12 Chemical Structure

CAS. Nr.: 1942843-54-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC₅₀ value of 5.41 nM.

IC₅₀ & Target

CDK9/cyclinT1

5.41 nM (IC₅₀)

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	2.1 nM Compound: 37	Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
HL-60	IC₅₀	44 nM Compound: 37	Antiproliferative activity against human HL-60 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
JeKo-1	IC₅₀	46 nM Compound: 37	Antiproliferative activity against human JeKo-1 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human JeKo-1 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
Kasumi 1	IC₅₀	21 nM Compound: 37	Antiproliferative activity against human Kasumi 1 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human Kasumi 1 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
MM1.S	IC₅₀	13 nM Compound: 37	Antiproliferative activity against human MM1.S cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human MM1.S cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
MV4-11	IC₅₀	1.6 nM Compound: 37	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
OCI-Ly10	IC₅₀	3.2 nM Compound: 37	Antiproliferative activity against human OCILY10 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human OCILY10 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
Raji	IC₅₀	37 nM Compound: 37	Antiproliferative activity against human Raji cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human Raji cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
RPMI-8226	IC₅₀	5.4 nM Compound: 37	Antiproliferative activity against human RPMI-8226 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human RPMI-8226 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
TMD8	IC₅₀	46 nM Compound: 37	Antiproliferative activity against human TMD8 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human TMD8 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]
Z-138	IC₅₀	46 nM Compound: 37	Antiproliferative activity against human Z138 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay Antiproliferative activity against human Z138 cells assessed as reduction in cell proliferation measured after 3 to 7 days by MTS assay	[PMID: 34477384]

Chemical Information

CAS. Nr. 1942843-54-0
Appearance Solid
Molecular Weight 378.85
Formel C₂₁H₁₉ClN₄O
Color White to off-white
SMILES

ClC1=C(C=C(C=N1)N[C@@H](CO)C2=CC=CC=C2)C3=CC=C(C4=C3)NN=C4C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (263.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6396 mL

13.1978 mL

26.3957 mL

5 mM

0.5279 mL

2.6396 mL

5.2791 mL

10 mM

0.2640 mL

1.3198 mL

2.6396 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Han X, et al. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2021 Oct 14;64(19):14647-14663. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6396 mL	13.1978 mL	26.3957 mL	65.9892 mL
	5 mM	0.5279 mL	2.6396 mL	5.2791 mL	13.1978 mL
	10 mM	0.2640 mL	1.3198 mL	2.6396 mL	6.5989 mL
	15 mM	0.1760 mL	0.8799 mL	1.7597 mL	4.3993 mL
	20 mM	0.1320 mL	0.6599 mL	1.3198 mL	3.2995 mL
	25 mM	0.1056 mL	0.5279 mL	1.0558 mL	2.6396 mL
	30 mM	0.0880 mL	0.4399 mL	0.8799 mL	2.1996 mL
	40 mM	0.0660 mL	0.3299 mL	0.6599 mL	1.6497 mL
	50 mM	0.0528 mL	0.2640 mL	0.5279 mL	1.3198 mL
	60 mM	0.0440 mL	0.2200 mL	0.4399 mL	1.0998 mL
	80 mM	0.0330 mL	0.1650 mL	0.3299 mL	0.8249 mL
	100 mM	0.0264 mL	0.1320 mL	0.2640 mL	0.6599 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CDK9-IN-12

Alle CDK Isoform-spezifische Produkte anzeigen